Crosstalk signaling in targeted melanoma therapy

@article{Meierjohann2017CrosstalkSI,
  title={Crosstalk signaling in targeted melanoma therapy},
  author={Svenja Meierjohann},
  journal={Cancer and Metastasis Reviews},
  year={2017},
  volume={36},
  pages={23-33}
}
Inhibition of the BRAF/MAPK pathway belongs to the standard therapies for patients with activating BRAFV600E/K mutations. However, even in well-responding tumors, anti-tumorigenic effect and clinical benefit are only transient, and the original tumors often relapse. This demonstrates that there are remaining residual tumors, which have withstood therapy-induced apoptosis and which have the potential to resume growth. Although BRAF mutant melanoma cells seem to depend on BRAF/MAPK signaling, the… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
4 Citations
86 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 86 references

Similar Papers

Loading similar papers…